These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32612152)

  • 1. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
    Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
    Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient.
    Monneret G; de Marignan D; Coudereau R; Bernet C; Ader F; Frobert E; Gossez M; Viel S; Venet F; Wallet F
    Cell Mol Immunol; 2020 Sep; 17(9):1001-1003. PubMed ID: 32728202
    [No Abstract]   [Full Text] [Related]  

  • 3. A plea for the pathogenic role of immune complexes in severe Covid-19.
    Vuitton DA; Vuitton L; Seillès E; Galanaud P
    Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
    Chu C; Sun Y; Pan Y
    Oral Oncol; 2020 Aug; 107():104860. PubMed ID: 32571643
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.
    Di Cosimo S; Malfettone A; Pérez-García JM; Llombart-Cussac A; Miceli R; Curigliano G; Cortés J
    Eur J Cancer; 2020 Aug; 135():62-65. PubMed ID: 32544799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
    Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
    Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating COVID-19 with colchicine in community healthcare setting.
    Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
    Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
    Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
    Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
    Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
    Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
    Calender A; Israel-Biet D; Valeyre D; Pacheco Y
    Trends Immunol; 2020 Oct; 41(10):856-859. PubMed ID: 32863134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
    Maio M; Hamid O; Larkin J; Covre A; Altomonte M; Calabrò L; Vardhana SA; Robert C; Ibrahim R; Anichini A; Wolchok JD; Giacomo AMD
    Clin Cancer Res; 2020 Aug; 26(16):4201-4205. PubMed ID: 32540850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
    Saxena A
    J Biosci; 2020; 45(1):. PubMed ID: 32661214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.
    Lin L; Lu L; Cao W; Li T
    Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
    Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
    [No Abstract]   [Full Text] [Related]  

  • 15. Surviving COVID-19: A disease tolerance perspective.
    Ayres JS
    Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause.
    Fernandez-Gutierrez B
    Reumatol Clin (Engl Ed); 2020; 16(4):253-254. PubMed ID: 32345483
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
    Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
    Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
    [No Abstract]   [Full Text] [Related]  

  • 18. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune characteristics of severe and critical COVID-19 patients.
    Yang L; Gou J; Gao J; Huang L; Zhu Z; Ji S; Liu H; Xing L; Yao M; Zhang Y
    Signal Transduct Target Ther; 2020 Aug; 5(1):179. PubMed ID: 32868756
    [No Abstract]   [Full Text] [Related]  

  • 20. NK cells: A double edge sword against SARS-CoV-2.
    Masselli E; Vaccarezza M; Carubbi C; Pozzi G; Presta V; Mirandola P; Vitale M
    Adv Biol Regul; 2020 Aug; 77():100737. PubMed ID: 32773100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.